Back to results
US 2026/0062703 A1Published application
Delivery of RNA Therapeutics Using Circular Prodrug Nucleic Acids
AssigneeARNAY Sciences LLC
InventorSudhir AGRAWAL
Life of this patent
Estimating the term…
Abstract
The present invention provides oligonucleotides referred to as circular prodrug nucleic acid (“CPN”) as described herein, compositions comprising same, and methods of using same. This design of circular prodrug nucleic acids maintains a circular form until the circularizing domain is cleaved in situ by RNase H or Dicer or other intracellular factors.
Claims33
A circular prodrug nucleic acid (CPN) comprising a functional domain and a circularizing domain,
- wherein the CPN comprises a structure according to Formula I or Formula II:
- wherein
- Y1-Yn is a first nucleic acid molecule;
- X1-Xm is a second nucleic acid;
- n is 0-44;
- and
- m is 0-44;
- wherein the nucleotides of the first nucleic acid molecule and the second nucleic acid molecule are independently selected from RNA or DNA, and wherein the first nucleic acid molecule and the second nucleic acid molecule are complementary to each other and of opposite polarity to each other and hybridize to form a double-stranded section.
5 more elements
33-36. (canceled)
Dependencies are inferred from the claim text.